
EUROPEAN HIV CLINICAL FORUM 2022

Hybrid Workshop | Paris, France | 7 June 2022



Program Book

virology education

AcademicMedicalEducation.com

EuropeanHCF2022_Programbook_A5_NV_HVR.indd 1 01/06/2022 11:15:06

EuropeanHCF2022_Programbook_A5_NV_HVR.indd 2 01/06/2022 11:15:06

Table of Contents

Needs Statement	4
Meeting Objectives	6
Practical Information	7
Program	8
Faculty	10
Acknowledgments	18

EuropeanHCF2022_Programbook_A5_NV_HVR.indd 3 01/06/2022 11:15:06

Needs Statement

Integrase inhibitors have become a preferred first-line regimen for the treatment of people living with HIV in most international treatment guidelines [1,2,3]. Clinical trials as well as real life data have shown them to be highly effective and well-tolerated, making them an attractive new drug class for HIV patients [4]. New integrase inhibitors and novel drug combination therapy strategies have emerged in recent years and are becoming widely available in more and more countries [5,6]. For example, the second generation INSTI dolutegravir is becoming increasingly available in a large number of resource limited countries worldwide. Bictegravir, also a second-generation integrase inhibitor is now available and widely used in many countries. Both dolutegravir and bictegravir are available as single tablet regimens with once daily dosing, low toxicity, and enduring viral suppression.

In addition, the now approved second generation INSTI cabotegravir is entering the clinical realm as an new option for clinicians in many countries. This long-acting drug would then offer new opportunities for patient care, not currently available.

The HIV field has also increasingly focused on prevention, including the use of ARV drugs as treatment for prevention (known as pre-exposure prophylaxis, or PrEP). Exceptionally large and well-designed studies have found this strategy to be extremely effective in preventing HIV aquisition when drugs are taken with good adherence. PrEP has been expanding at a rapid rate, including both resource rich and limited settings. The FDA recently approved a new drug for PrEP which maintains the high efficacy with even smaller potential for toxicity. Long-acting PrEP formulations will also be an option.

Dolutegravir dosed twice daily has become a corner stone of treatment for highly treatment experienced patients [7, 8]. Recently approved drugs with new mechanisms of action including ibalizumab and fostemsavir can improve care of this hard-to-treat patient population [9, 10]. There is an urgent need to educate HIV treating clinicians on how best to incorporate these new drugs together with current options such as DTG and DRV/r in highly treatment experienced patients. New investigational drugs such as islatravir and lenacapavir may also soon be entering the clinical realm as additional options for these patients [11, 12].

There are now close to ten different formulations and combination pills which include an integrase inhibitor. These continue to be studied in a variety of prospective and retrospective clinical trials, both for treatment and prevention. Clinicians need to be knowledgeable of these drugs and how they might impact optimal patient care. Even the most competent and diligent HIV practicing clinician cannot possibly keep up with the pace of new important data emerging.

The five approved INSTI differ substantially in their pharmacological (dosing schedule, need for pharmacological boosting, drug-drug interactions profile) and virological (genetic barrier to resistance) characteristics. This is further complicated by the different formulations and combination pills. New data on therapy options are being presented and published at a high rate. These data have the potential to impact optimal patient care, but it is a challenge for busy clinicians to stay informed about these rapid developments and to continue providing the best treatment available for their patients. To keep current with these latest developments, there is a need for a platform that effectively informs clinicians and other healthcare professionals of them in an efficient and clinically relevant manner. Additionally, clinicians need to be able to exchange their experiences and get

EuropeanHCF2022_Programbook_A5_NV_HVR.indd 4 01/06/2022 11:15:06

the opportunity to discuss with experts in the field about how to optimally apply the latest insights on new drugs and new treatment and prevention strategies in their practice.

However, it is also crucial that this information is tailored to the local and regional needs and context of care. Regional and local circumstances may vary greatly and can have a major impact on clinicians' optimal use of these drugs and treatment strategies. Additionally, studies are commonly published in English, which can present another barrier for clinicians in many areas. All this needs to be kept in mind while designing optimal educational programs for HIV treating clinicians.

No doubt the coming years will see new opportunities opening to the HIV treating clinician. Novel treatment strategies, long-acting parenteral preparation allowing infrequent dosing and other developments will need to be learned and understood. Educational programs must include all these in their focus.

The need for programs to update clinicians on new treatment and prevention strategies is clearly demonstrated by the results of our ongoing survey performed at our Forum meetings. In 2020, more than 2700 Health Care Professionals (60% MDs) participated in our HIV Clinical Forum program worldwide. On average, the attendees consult more than 200 patients per months. Furthermore, almost 80% of the participants indicated that they intend to use the gained knowledge in the clinical management of their patients. Therefore, the impact of these programs on improved patient care was extensive.

To conclude, there is a need for a platform that will help healthcare practitioners to stay ahead of the developments in the field as this will greatly affect patient management and quality of life of people living with HIV. As the data continues to grow and evolve, clinicians must have tools to evaluate these data and their application into routine clinical care for the optimal benefit of their patients.

1. WHO - Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection; http://www.who.int/hiv/pub/arv/arv-2016/en/
2. EACS – Guidelines 8.1 October 2016; http://www.eacsociety.org/files/guidelines_8.1-english.pdf
3. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2016 Recommendations of the International Antiviral Society–USA Panel; https://www.iasusa.org/content/antiretroviral-drugs-treatment-and-prevention-hiv-infection-adults-2016-recommendations
4. Kanters S, et al. Lancet HIV. 2016; 3(11):e510-e520.
5. Han Y, Mesplède T, Wainberg MA. Expert Opin Investig Drugs. 2017;26(11):1207-1213.
6. Boffito M and Venter F. Lancet. 2017; 390(10107):2019–2021
7. Castagna, A. et al; Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014 Aug 1;210(3):354-62. doi: 10.1093.
8. A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. (VIKING-3) https://clinicaltrials.gov/ct2/show/NCT01328041
9. Emu, B. et al; Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med 2018; 379:645-654 / DOI: 10.1056/NEJMoa1711460
10. Kozal, M. er al. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. N Engl J Med 2020; 382:1232-1243 / DOI: 10.1056/NEJMoa1902493
11. Molina, J-M. et al. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial. Lancet volume 8, issue 6, e324-e333, June 01, 2021.
12. Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA). https://clinicaltrials.gov/ct2/show/NCT04150068

EuropeanHCF2022_Programbook_A5_NV_HVR.indd 5 01/06/2022 11:15:06

Meeting Objectives

Meeting Objectives

With the HIV Clinical Forum program we aim to:

- Build a community of healthcare professionals devoted to providing optimal clinical care for their patients.
- Create a platform for interactive information exchange on novel treatment strategies and options.
- Translate the latest studies and research achievements into clinical guidance for the optimal management of people living with HIV

Learning Objectives

After participating in the HIV Clinical Forum, participants will be able to:

- Understand the scientific rationale and clinical data supporting novel treatment strategies;
- Describe the pros and cons of novel treatment strategies and drugs;
- Understand how to integrate novel treatment strategies into routine patient care;
- Be knowledgeable of the clinical data supporting long-acting injectable regimens;
- Identify patients who might most benefit from long-acting injectable regimens;
- Gain knowledge on how to optimally integrate injectable drugs into routine clinical care;
- Improve their skills in defining and identifying treatment-experienced people living with HIV;
- Stay informed on new drug options for treatment-experienced patients;
- Understand how best to use new treatment options for highly treatment-experienced patients.

CME Accreditation

The **European HIV Clinical Forum 2022**, Paris, France, 07/06/2022-07/06/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **5 European CME credits** (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EuropeanHCF2022_Programbook_A5_NV_HVR.indd 6 01/06/2022 11:15:06

Badge Policy
All registered delegates are provided with an identity badge. Please wear it at all times to ensure admission to the meeting.

Certificate of Attendance
A certificate of attendance will be sent by e-mail following the meeting.

Conference Language
The official language of the meeting is English.

Conference Secretariat
The Conference Secretariat is located at the registration desk in the pre-function area of the conference room. It is open throughout the conference to address all your questions concerning logistics.

Conference Website
More information regarding the program and logistics of the conference can be found on our website at academicmedicaleducation.com/meeting/european-hiv-clinical-forum-2022.

Currency
The euro (€) is the official currency of France.

Enduring Materials
Webcasts of the presentations, along with the PDF presentations will be available on www.AcademicMedicalEducation.com shortly after the meeting, granted we have received the speakers' permission.

Feedback Form
Your feedback is very valuable and enables us to further improve this meeting. A post-meeting survey will be sent out to you following the meeting, and a certificate of attendance will be provided upon completion of the post-meeting survey.

Group Photo
Instructions will be provided by the session chair. Please follow further instructions from the on-site team.

Time Zones
Times are in Central European Summer Time (CEST). If you need to convert the times to your timezone, this website can help you: www.worldtimebuddy.com.

Virtual Platform
OnAIR is the virtual conference platform being used for European HIV Clinical Forum 2022. Please check with our staff for login details to access the virtual platform.

Wi-Fi
Wi-Fi will be available during the entire meeting. Please check with our staff for login details.

Disclaimer: This conference aims to offer participants the opportunity to share information. Virology Education cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaim all liability for injuries or losses of whatever nature incurred by individuals attending the conference.

7 June 2022

9:00 CEST – 16:35 CEST

9:00	**Opening of the Meeting** **Jonathan Schapiro, MD** National Hemophilia Center, Sheba Medical Center, Israel **Anne-Geneviève Marcelin, MD** Hôpital Pitié-Salpétrière Paris, France	
Session 1	**Antiretroviral Therapy 2022 - State of ART Plenary Lectures**	
09:10	**International and European Guidelines - Similarities and Differences** **Caroline Sabin, PhD** Medical Statistics and Epidemiology, University College London (UCL), United Kingdom	
09:35	**Resistance Considerations in Choice of Regimen** **Daniele Armenia, PhD** Saint Camillus International University of Health Sciences, Italy	
10:00	**Pharmacological Considerations in Choice of Regimen** **Saye Khoo, MD, PhD** Royal Liverpool University Hospital; University of Liverpool, United Kingdom	
10:25	**Comorbidity and Toxicity Considerations in Choice of Regimen** **Esteban Martínez, MD, PhD** Hospital Clínic & University of Barcelona, Spain	
10:50	**Discussion** **Caroline Sabin, PhD** Medical Statistics and Epidemiology, University College London (UCL), United Kingdom **Daniele Armenia, PhD** Saint Camillus International University of Health Sciences, Italy **Saye Khoo, MD, PhD** Royal Liverpool University Hospital; University of Liverpool, United Kingdom **Esteban Martínez, MD, PhD** Hospital Clínic & University of Barcelona, Spain	
11:00	Coffee Break	
Session 2	**Starting and Switching Antiretroviral Therapy in 2022**	
11:30	**Update on Therapeutic Options for Starting and Switching** **Sanjay Bhagani, BSc, FRCP** Royal Free Hospital, United Kingdom	
11:55	**Considerations in Switching to Newer Regimens in Patients Suppressed on Older Drugs** **Gary Rubin, MD, MCFP, AAHIVS** University of Toronto, Canada	
12:20	**Clinical Case (Focused on Starting and Switching Therapy)** **Miłosz Parczewski, MD, PhD** Pomeranian Medical University, Poland	
12:35	**Discussion** **Sanjay Bhagani, BSc, FRCP** Royal Free Hospital, United Kingdom **Gary Rubin, MD, MCFP, AAHIVS** University of Toronto, Canada **Miłosz Parczewski, MD, PhD** Pomeranian Medical University, Poland	
12:45	Lunch Break	

EuropeanHCF2022_Programbook_A5_NV_HVR.indd 8 01/06/2022 11:15:07

Session 3	**HIV Prevention in 2022**
13:45	**Update on Therapeutic Options for HIV Prevention** **David Jilich, MD** Hospital Na Bulovce, Czech Republic
14:15	**How to Choose Between Oral and IM PrEP for Each Individual** **Jean-Michel Molina, MD, PhD** Saint-Louis/Lariboisière Hospitals and University of Paris, France
14:35	**Clinical Case (Focused on Prevention)** **Emma Rubenstein, MD, MPH** Hôpital Saint-Louis, France
14:50	**Discussion** **David Jilich, MD** Hospital Na Bulovce, Czech Republic **Jean-Michel Molina, MD, PhD** Saint-Louis/Lariboisière Hospitals and University of Paris, France **Emma Rubenstein, MD, MPH** Hôpital Saint-Louis, France
15:00	Coffee Break
Session 4	**Optimal Care of Highly Treatment Experienced Patents - Now and in the Future**
15:30	**Current and Evolving Therapeutic Options for Highly Treatment Experienced Patients** **Daniel Kuritzkes, MD** Brigham and Women's Hospital; Harvard Medical School, United States
15:55	**Integrating Multiple Novel Agents for Optimal Care of Multiclass Resistant Patients** **Anna Maria Geretti, MD, PhD, FRCPath** University of Rome, Italy; King's College London, United Kingdom
16:10	**Clinical Case (Focused on Highly Treatment Experienced Patients)** **Josep Llibre, MD, PhD** Fundació Lluita contra la Sida; Hospital Universitari Germans Trias i Pujol, Spain
16:25	**Discussion** **Daniel Kuritzkes, MD** Brigham and Women's Hospital; Harvard Medical School, United States **Anna Maria Geretti, MD, PhD, FRCPath** University of Rome, Italy; King's College London, United Kingdom **Josep Llibre, MD, PhD** Fundació Lluita contra la Sida; Hospital Universitari Germans Trias i Pujol, Spain
	End of Program
16:35	**Closing Remarks by the Forum Chairs** **Jonathan Schapiro, MD** National Hemophilia Center, Sheba Medical Center, Israel **Anne-Geneviève Marcelin, MD** Hôpital Pitié-Salpétrière Paris, France
	Networking Reception

EuropeanHCF2022_Programbook_A5_NV_HVR.indd 9 01/06/2022 11:15:07

Faculty



Program Director

Jonathan Schapiro, MD, PhD

National Hemophilia Center, Sheba Medical Center, Israel



Local Chair

Anne-Geneviève Marcelin, MD

Hôpital Pitié-Salpétrière Paris, France

Jonathan M Schapiro, MD has devoted his career to HIV clinical care, research and education since completing his Fellowship in Infectious Diseases and Geographic Medicine at the Stanford University School of Medicine Center For AIDS Research, Stanford CA. Dr. Schapiro Graduated from the Ben Gurion University School of Medicine and completed his Medicine Residency at the Rabin Medical Center in Israel.

Dr. Schapiro's research has focused on the causes of antiretroviral drug failure, interventions to optimize clinical care, and new drug development. His interests have include resistance and cross-resistance between drugs, associations between resistance and pharmacology, development of new antiretroviral agents with improved resistance and pharmacological profiles, the clinical utility of resistance and drug level testing, and integrating resistance assays and other diagnostics into clinical care. He has been involved in the development of advanced interpretation systems for these assays, and has worked to highlight the importance of interactions between drug exposure and resistance. Dr. Schapiro currently runs the HIV/AIDS clinic at the National Hemophilia Center in Tel Aviv, Israel.

Anne-Genevieve Marcelin is Professor of Medicine at Sorbonne Université in Paris, France and clinical virologist at the Pitié-Salpêtrière Hospital. She's head of a research team (Inserm UMR 1136) dedicated to Therapeutic strategies for HIV infection and associated viral diseases.

Pr Anne-Genevieve Marcelin research interests include HIV mechanisms of resistance to antiretrovirals, new therapy strategies for HIV treatment and new antiretroviral agents. She serves as a member of Agence Nationale de Recherches sur le SIDA et les hepatites virales (ANRS), in the French AC43 resistance group (www.hivfrenchresistance.org) and is chair of the ANRS Next generation sequencing network.

She's member of the WHO Steering Group that provides high level guidance and supports in developing and implementing WHO global HIV drug resistance prevention, surveillance and response strategy and is co-chair of the WHO Working Group 3, on Research and Innovation.

EuropeanHCF2022_Programbook_A5_NV_HVR.indd 10 01/06/2022 11:15:08



Daniele Armenia, PhD

Saint Camillus International University of Health Sciences, Italy

Researcher at "Saint Camillus International University of Health Sciences" of Rome. He earned a graduation in Pharmaceutical Biotecnology at University of Bologna and a PhD in Medical Microbiology and Immunology at the University of Rome "Tor Vergata". He was a research fellow at the Department of Virology of the University of Rome "Tor Vergata" for several years. During this period, he also worked abroad in clinical research centres and diagnostic companies, carrying out research focused on virology fields, in particular on: the impact of antiretroviral treatments on HIV infection; the mechanisms of resistance to HIV, HBV and HCV drugs; the fitness and viral evolution of HIV and hepatitis viruses; the genotypic, phenotypic, structural and functional analysis of viral proteins. His research activity carried out numerous publications in international journals and he has participated in numerous national and international conferences.

Associate professor at UniCamillus.



Sanjay Bhagani, BSc, FRCP

Royal Free Hospital, United Kingdom

Sanjay Bhagani, BSc FRCP is a consultant physician in Infectious Diseases/HIV Medicine and General (internal) Medicine at the Royal Free Hospital in London, and the current President at EACS. He has a specialist interest in the management of HIV in-patients with complex multi-system and opportunistic infections and patients with viral hepatitis co-infections.

Dr Bhagani has been at the forefront of provision of clinical care for patients with severe and critical COVID-19 through the two waves of the pandemic in London. He is the Clinical Lead for interventional clinical trials for COVID-19 at the Royal Free Hospital.

Faculty



Anna Maria Geretti, MD, PhD, FRCPath

University of Rome, Italy; King's College London, United Kingdom

Professor Anna Maria Geretti – MD, PhD – is an academic clinician who specializes in virology, with a focus on antiviral therapy and drug resistance. She is based in the United Kingdom and in Italy and is affiliated with the Departments of Infectious Diseases of King's College London and the University of Rome Tor Vergata. Her research, primarily for translation of science into clinical care applications, has led to over 250 publications spanning laboratory-based, patient-side, and epidemiology projects, which includes fieldwork in sub-Saharan Africa, collaborations with the World Health Organization, and drug and biomarker development within the industry. Anna Maria is Editor in Chief of the BMJ journal Sexually Transmitted Infections. Her ambition is to deliver an impact that promotes the progress of medicine and science and is globally beneficial to patient care.



David Jilich, MD

Hospital Na Bulovce, Czech Republic

David Jilich, MD is the Head of the HIV Centre Prague and Deputy Head of the Department of Infectious, Parasitic and Tropical Diseases at Na Bulovce Hospital, which has the largest number of HIV patients in the Czech Republic. He is an infectious disease specialist and his main focus is HIV. He is an Assistant Professor at the First Faculty of Medicine, Charles University in Prague. In addition to his clinical and teaching activities, he has also engaged in research at the regional and international levels (EuroSIDA, START) for many years. He has published over 60 articles in international journals. He is a member of the European AIDS Clinical Society and was a member of the Scientific Committee at the 17th annual EACS Conference in Basel, Switzerland in autumn 2019.

EuropeanHCF2022_Programbook_A5_NV_HVR.indd 12 01/06/2022 11:15:09



Saye Khoo, MD, PhD

Royal Liverpool University Hospital; University of Liverpool, United Kingdom

Professor Saye Khoo, MD, PhD, is Honorary Consultant Physician in Infectious Diseases at the Royal Liverpool University Hospital, and Professor in the School of Biomedical Sciences at the University of Liverpool. His research focuses on the pharmacology of HIV treatment failure and how therapy may be improved through individualised care through understanding of why drug exposure varies markedly between individuals (and the role of individual characteristics such as weight, gender, host genetics and drug interactions), and identify vulnerable groups who are at particular risk of failure, or toxicity. These studies span bench science, through translational research and into the clinic, and onwards to population based modelling approaches.



Daniel Kuritzkes, MD

Brigham and Women's Hospital; Harvard Medical School, United States

Daniel Kuritzkes is the Harriet Ryan Albee Professor of Medicine at Harvard Medical School and Chief of the Division of Infectious Diseases at Brigham and Women's Hospital in Boston, Massachusetts. He received his B.S. and M.S. degrees from Yale University and his M.D. from Harvard Medical School. Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and previously chaired the AIDS Clinical Trials Group. He served as a member of the NIH Office of AIDS Research Advisory Council and as a member of the U.S. Department of Health and Human Services panel on guidelines for antiretroviral therapy. He has been a member of several editorial boards and serves an Associate Editor of the Journal of Infectious Diseases. His research interests focus on HIV therapeutics, antiretroviral drug resistance, and HIV eradication.

Faculty



Tetiana Kyrychenko, MD, PhD

Poltava Regional HIV/AIDS Prevention And Control Center, Ukraine



Josep Llibre, MD, PhD

Fundació Lluita contra la Sida; Hospital Universitari Germans Trias i Pujol, Spain

Tetyana Kyrychenko, MD, PhD, received her graduation in Medicine at the Ukrainian Medical Stomatological Academy, Poltava, Ukraine in June 2007 and then decided to enter the School of Specialization in Infectious Disease. She received her scientific degree of a candidate of medical sciences (PhD) in 2014. Thesis: "Clinical and epidemiological characteristic of HIV-infection and the treatment effectiveness estimation based on role detection of Asp299Gly TLR4 gene polymorphism".

Dr. Kyrychenko currently works as infectious diseases physician at the Out-Patients department of Poltava Regional HIV/AIDS Prevention and Control Center since 2009. In addition, she is on a partial academic position as assistant professor at the Department of microbiology, virology and immunology, Ukrainian Medical Stomatological Academy.

HIV has always been her main field of interest and still now she is personally taking care of more than 800 patients. Her special focus is HIV positive active injected drug users, people on methadone substitution.

She currently holds a professional membership at the International AIDS Society and European AIDS Clinical Society and is one of the EACS Governing Board members since 2021. Dr. Kyrychenko is a member of the scientific

Dr Josep M Llibre, received his MD in the Universitat de Barcelona, and obtained his specialty in Internal Medicine and his PhD in the Universitat Autònoma de Barcelona with his research on the Clinical Impact of HIV resistance against non-nucleoside reverse transcriptase inhibitors. He does clinical assistance and clinical research in the Infectious Diseases Dept. of the Germans Trias I Pujol University Hospital.

He has been a panel member of the Antiretroviral treatment guidelines at the GeSIDA group, and an expert advisor of the Catalan Health Institute (ICS) on antiretroviral treatment and hepatitis C (PADEICS). He started caring for patients with HIV/AIDS at the beginning of the epidemic in Spain in 1987. His main areas of interest in HIV Medicine include the clinical implications of HIV-1 resistance, the analysis of safety and efficacy in HIV-1 antiretroviral treatment clinical trials (both in naïve and pre-treated patients), with special interest in drug efficacy, new treatment strategies and pharmaco-economics.

He has published widely in journals and book chapters, as well as HIV/AIDS medical webs, on clinical aspects of HIV-1 treatment and care, HIV-1 resistance, clinical reviews, positioning papers, treatment intensification and simplification strategies, and participated in many pivotal clinical trials. He is involved in HIV Medical Educational training in Spain and other European countries, and has participated in long-distance expert advice support strategies for complex HIV patients in Spain.

EuropeanHCF2022_Programbook_A5_NV_HVR.indd 14 01/06/2022 11:15:25



Esteban Martínez, MD, PhD

Hospital Clínic & University of Barcelona, Spain



Jean-Michel Molina, MD, PhD

Saint-Louis/Lariboisière Hospitals and University of Paris, France

Dr Esteban Martínez is a Senior Consultant in Infectious Diseases at Hospital Clínic of Barcelona (Spain) and Associate Professor of Medicine at University of Barcelona. He is professionally devoted to HIV clinical care and research. He has worked in different educational projects with community-based organisations over many years in Spain: Projecte dels Noms-Hispanosida, Gais Positius, and Grupo de Trabajo de Tratamientos sobre VIH. He currently holds the positions of past president of the Spanish AIDS Study Group (GESIDA) and vice-president of European AIDS Clinical Society (EACS). He is a member of the Scientific Board of the International Workshop on Adverse Drug Reactions and Co-morbidities in HIV.

He has been co-author of the Spanish Guidelines on Antiretroviral Therapy, Metabolic, Kidney, Bone, and Neuropsychiatric Complications in HIV-Infected patients (GESIDA); and the Guidelines for the Prevention and Management of Non-Infectious Co-Morbidities in HIV (EACS).

He is a member of the Editorial Board of the following journals: AIDS, AIDS Research and Therapy, Clinical Infectious Diseases, HIV Medicine, Journal of Acquired Immunodeficiency Syndromes, Journal of Antimicrobial Chemotherapy, and Journal of Infectious Diseases.
His fields of interests span antiretroviral therapy strategies, toxicity of antiretrovirals, non-infectious complications, co-morbidities, and aging in adults living with HIV.

Jean-Michel Molina, MD, PhD, is Professor of Infectious Diseases at the University of Paris, and Head of the Infectious Diseases Department at the Saint-Louis and Lariboisière Hospitals in Paris, France. The Department of Infectious Diseases is mainly involved in the care of immunocompromised patients, patients with HIV infection, bone marrow and renal transplant recipients, and patients with haematological malignancies and cancers.

Professor Molina's primary clinical research interest focuses on HIV infection, initially the treatment of AIDS-related opportunistic infections, and then the treatment of HIV infection. He has been involved in a number of studies assessing new drugs or new strategies for the treatment of HIV infection. He is also a member of the French National Institute of Health and Medical Research (INSERM) U944 team at the Saint-Louis Hospital investigating cell biology of viral infections. Professor Molina is also involved in the French National Agency for AIDS Research (ANRS), where he chaired the clinical trial group for the last 12 years.

More recently, Professor Molina has broadened his field of interest to the prevention of HIV infection with antiretrovirals and has led the ANRS IPERGAY pre-exposure prophylaxis trial in men who have sex with men. A cohort of more than 3,500 people on PrEP is followed in his unit, and a new ANRS PrEP study (ANRS Prevenir) is implemented in the Paris region to contain the HIV epidemic among men who have sex with men.

Faculty



Miłosz Parczewski, MD, PhD

Pomeranian Medical University, Poland

Miłosz Parczewski, MD, PhD has received the MD diploma at the Pomeranian Medical University, Poland in 2002 and was granted a PhD diploma in molecular epidemiology in 2007. He is a practicing infectious diseases specialist (ID specialist diploma obtained in 2011), being currently a head and associate professor at the Department of Infectious, Tropical Diseases and Acquired Immunodeficiency Pomeranian Medical University, Szczecin, Poland.

His research focuses on the molecular epidemiology in HIV infection and HCV coinfection: aspects of the genetic variability of the host with the key interest in chemokine and interleukin receptor genes, HIV genetic variability - evolution of drug resistance and tropism, phylogeographic tracing of the viral transmission and recombination. Furthermore, he investigates association between genetic HIV-1 infection susceptibility and survival and variants of the host associated with the drug adverse reactions. He is a vice-president of the Polish Scientific AIDS Society and a member of European Society on Antiviral Resistance.



Emma Rubenstein, MD, MPH

Hôpital Saint-Louis, France

Emma Rubenstein, MD, MPH is assistant physician in the Department of Infectious Diseases at Saint-Louis Hospital in Paris, France. She treats patients with HIV infection, hepatitis B and C, and also takes part in pre-exposure prophylaxis (PrEP). She is involved in several research protocols regarding the treatment of HIV, the prevention and treatment of sexually-transmitted diseases, and PREP.

EuropeanHCF2022_Programbook_A5_NV_HVR.indd 16 01/06/2022 11:15:44



Gary Rubin, MD, MCFP, AAHIVS

University of Toronto, Canada

Gary Rubin is a graduate of Dalhousie University in Halifax Nova Scotia and currently Assistant Professor in the Department of Family and Community Medicine at the University of Toronto and Sunnybrook Health Sciences Center. He is the Medical Director at CW Health, a Multi Disciplinary Clinic specializing in the treatment of people living with HIV. He is a member of the Medical Advisory Boards for Gilead and VIIV and has been involved in many Phase II and Phase III HIV clinical trials. He is also a member of the Credentialing Committee of the American Academy of HIV Medicine. Recently he has also been a consultant on COVID-19 to major financial institutions.



Caroline Sabin, PhD

Medical Statistics and Epidemiology, University College London (UCL), United Kingdom

Caroline Sabin is a Professor of Medical Statistics and Epidemiology at UCL, the Director of the NIHR Health Protection Research Unit in Blood-Borne and Sexually Transmitted Infections at UCL, and the current vice-chair of the British HIV Association (BHIVA).

Caroline's interests are in describing the natural history of HIV infection, identifying prognostic markers and describing outcomes of treatment. She established the UK Collaborative HIV Cohort (UK CHIC) Study, was the principal statistician/co-lead for the D:A:D Study, and is the co-principal investigator for the POPPY study, a large cohort that investigates the associations of aging and HIV in the UK and Ireland.

Acknowledgments

Support

SUPPORTER



The **European HIV Clinical Forum 2022** is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

ENDORSERS

BCN checkpoint MEN · SEX · HEALTH

clinical cases DDIs

EATG European AIDS Treatment Group

FLS SCIENCE FOSTERING LEARNING & SHARING

FUNDAÇÃO PORTUGUESA A COMUNIDADE CONTRA A SIDA

IAPAC INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE

LID Lithuanian Society for Infectious Diseases

NATAP NATIONAL AIDS TREATMENT ADVOCACY PROJECT www.natap.org

EuropeanHCF2022_Programbook_A5_NV_HVR.indd 18 01/06/2022 11:15:49

Notes

EuropeanHCF2022_Programbook_A5_NV_HVR.indd 19 01/06/2022 11:15:49

academic
medical education

AcademicMedicalEducation.com

EuropeanHCF2022_Programbook_A5_NV_HVR.indd 20 01/06/2022 11:15:49